Concord Drugs Ltd

BSE: 538965

total announcements

538965.BO · 15 min delayed

BSEResultResults1d ago

Concord Drugs Ltd

Board of Directors have approved stand alone and consolidated Un-audited financial results for 30th June 2026

Concord Drugs Ltd has announced its unaudited financial results for the quarter ended 30th June 2026, showing revenue from operations of Rs. 2,088.86 lakhs and a net profit of Rs. 111.23 lakhs. The company's earnings per share (EPS) for the quarter is Rs. 0.84. The financial results are available on the company's website and on the BSE website.

Outcome of Board meeting

Concord Drugs Ltd announces its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 2,088.86 lakhs and profit before tax at Rs. 154.26 lakhs.

Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve Quarterly Results

Concord Drugs Ltd has scheduled a board meeting on 10/08/2026 to consider and approve the un-audited financial results for the quarter ended 30/06/2026.